Adma Biomanufacturing was Adma Biologics’s largest segment in fiscal 2025, bringing in $362.53M of $377.44M (96%).
| Segment | FY 2011 | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biomanufacturing | $144.07M | $140.21M | $239.59M | $362.53M | ||||||||||
| Component Of Adma Biomanufacturing That Usually Provides Financial, Operational & Administrative Support And Is Considered An Operating Segment | — | — | — | — | ||||||||||
| Plasma Collection Centers | $9.87M | $8.33M | $10.51M | $14.91M | ||||||||||
| Component Of Plasma Collection Centers Segment That Usually Provides Financial, Operational & Administrative Support And Is Considered An Operating Segment | — | — | — | — | ||||||||||
| Plasma Collection Center | — | — | — | — | ||||||||||
| Corporate | — | — | — | — | ||||||||||
| Total | $153.94M | $148.55M | $250.10M | $377.44M |
Adma Biologics brought in $377.44M from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $499.25M it reports by geography, so these segments do not cover all of its revenue. Adma Biomanufacturing was the largest at $362.53M (96.1%), ahead of Plasma Collection Centers at $14.91M (3.9%).
Compared with fiscal 2024, Adma Biomanufacturing grew 51.3% to $362.53M and Plasma Collection Centers grew 41.9% to $14.91M.
United States was Adma Biologics’s largest region in fiscal 2025, bringing in $489.16M of $499.25M (98%).
| Geography | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| United States | $146.43M | $237.60M | $400.48M | $489.16M | ||
| International | $7.65M | $12.28M | $15.47M | $10.09M | ||
| Total | $154.08M | $249.88M | $415.95M | $499.25M |
Adma Biologics brought in $499.25M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 20.0% from $415.95M in fiscal 2024. United States was the largest at $489.16M (98.0%), ahead of International at $10.09M (2.0%).
Compared with fiscal 2024, United States grew 22.1% to $489.16M, while International fell 34.8% to $10.09M. From fiscal 2022 to 2025, combined revenue from these regions grew from $154.08M to $499.25M, a compound annual growth rate of 48.0%. United States' share of the total rose from 95.0% to 98.0%.
Product Revenue was Adma Biologics’s largest product and service line in fiscal 2020, bringing in $42.08M of $42.22M (100%).
| Product and Service | FY 2020 |
|---|---|
| Product Revenue | $42.08M |
| License Revenue | $142.83K |
| Total | $42.22M |
Adma Biologics brought in $42.22M from its two product and service lines in fiscal 2020, the year ended December 31, 2020. Product Revenue was the largest at $42.08M (99.7%), ahead of License Revenue at $142.83K (0.3%).
Adma Biologics (ADMA) reports its revenue by segment, by geography and by product and service. In fiscal 2025, Adma Biomanufacturing was its largest segment, bringing in $362.53M (96.1% of the total), followed by Plasma Collection Centers at $14.91M (3.9%).
Adma Biomanufacturing was Adma Biologics' largest segment in fiscal 2025, bringing in $362.53M, or 96.1% of the $377.44M total across its two segments.
United States was Adma Biologics' largest region in fiscal 2025, bringing in $489.16M, or 98.0% of the $499.25M total across its two regions.
Product Revenue was Adma Biologics' largest product and service line in fiscal 2020, bringing in $42.08M, or 99.7% of the $42.22M total across its two product and service lines.
Adma Biomanufacturing grew faster than Plasma Collection Centers in fiscal 2025, up 51.3% from $239.59M to $362.53M. Plasma Collection Centers grew 41.9% to $14.91M.
Every figure comes from Adma Biologics' annual financial filings, as reported. Each line keeps the name Adma Biologics gives it, and years follow its fiscal calendar.
Adma Biologics' revenue by segment goes back to fiscal 2011, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.